ebr logo bar
February 2024  Volume 22, Number 2        

The Shocking High Cost of Covering Obesity Drugs

A new survey reveals that the costs of covering increasingly popular obesity drugs like Ozempic and Wegovy are quickly mounting for employers. But with demand from employees high and potential health benefits significant, more companies are considering taking on the pricey medications.

Costs Add Up

According to a survey of 200 employers from the International Foundation of Employee Benefit Plans (IFEBP), the average representation of glucagon-like peptide-1 (GLP-1) drugs prescribed for weight loss amounted to 6.9% of respondents' total annual prescription claims costs in 2023.

With the average cost of these obesity medications exceeding $1,000 per month per patient, it's no wonder employers are concerned about the financial impact. Providing coverage for more employees could quickly inflate costs.

Currently, just 22 percent of employers surveyed said they cover GLP-1 drugs for weight loss purposes, while 76 percent cover them for diabetes — the original intended use.

Of those covering the medications for weight loss, 79 percent said they rely on prior authorization to control costs. Step therapy was less common at 32 percent, and 14 percent have no cost control mechanism in place.

Weighing Pros and Cons

With employee interest and demand rising, nearly half of employers (43 percent) now say they plan to add coverage for obesity medications like Ozempic and Wegovy in 2024. That's almost double the number covering them today.

Experts say the increase is likely driven by enthusiasm from employees who see the potential benefits, as well as interest from employers themselves who see weight loss as a way to reduce the risk of costly comorbidities such as heart disease and diabetes. Providing access could also be a recruitment and retention strategy.

However, many companies remain cautious due to the high monthly costs per patient. Other factors, like potential long-term side effects and unknowns about the drugs' lasting effectiveness, also contribute to hesitance from employers.

[return to top]





In this issue:

This Just In ... The Shocking High Cost of Covering Obesity Drugs

Six Healthcare Trends Employers Can't Afford to Ignore in 2024

How to Attract and Retain Top Talent in 2024

What the Transformation of PBMs Could Mean for Employers

How Tailored Benefits Can Support Women in Today's Workforce



The information presented and conclusions within are based upon our best judgment and analysis. It is not guaranteed information and does not necessarily reflect all available data. Web addresses are current at time of publication but subject to change. SmartsPro Marketing and The Insurance 411 do not engage in the solicitation, sale or management of securities or investments, nor does it make any recommendations on securities or investments. This material may not be quoted or reproduced in any form without publisher's permission. All rights reserved. ©2024 Smarts Publishing https://smartspublishing.com/ Tel. 877-762-7877.